Biacore's Analysts Conference Call - Clarification

Biacore's Analysts' Conference Call - Clarification Uppsala, Sweden, July 23, 2001. At Biacore International AB's (Biacore) (SSE: BCOR; Nasdaq: BCOR) conference call today after the release of the Company's half-year report, Ulf Jönsson, in response to a question regarding the net margin, replied that, on a quarterly basis, the Company's net margin could fall below 10%. This answer seems to have been interpreted as referring to the full-year 2001. This interpretation is incorrect, as Biacore has a policy of not making profit forecasts. This press release contains certain forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, which, by their nature, involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements. Biacore is a global market leader in Surface Plasmon Resonance (SPR) based technology with its own sales operations in the U.S., across Europe, in Japan, Australia and New Zealand. The technology is protected by a strong patent portfolio. Target groups consist primarily of medical and life science research laboratories and pharmaceutical and biotechnology companies all over the world. Biacore focuses on drug discovery as the prime area for future growth. The company currently has six systems on the market with its BIACORE®3000 system offering specific application in drug discovery processes upstream of high-throughput screening (HTS). A new high-performance system is currently under late- stage development and will focus on applications downstream of HTS. Based in Uppsala, Sweden, the company is listed on Stockholmsbörsen and Nasdaq in the U.S. In 2000 the company has sales of SEK 438.8 million and an operating income of SEK 78.0 million. Further information on Biacore can be found on the web: www.biacore.com Address and phone: Biacore International AB Rapsgatan 7, SE-754 50 Uppsala, SWEDEN Phone: +46 (0)18-675700 Fax: +46 (0)18-150111 info@biacore.com For further information, please contact: Ulf Jönsson, President +46 (0) 18 67 57 52 or 46 (0)703 24 80 88 Scientific/Trade Press Enquiries: Debbie Staines, HCC.De Facto Group +44 (0) 207 496 3300 ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2001/07/23/20010723BIT00250/bit0001.doc http://www.waymaker.net/bitonline/2001/07/23/20010723BIT00250/bit0001.pdf

About Us

Biacore™ systems for label-free interaction analysis generate unique data on molecular interactions, giving insights into biological functions and disease mechanisms, and facilitating efficient therapeutic development. Application areas include drug discovery, general life science research, antibody characterization, immunogenicity, biotherapeutic development and manufacture. Biacore AB is a GE Healthcare company. Further information: www.biacore.com

Subscribe